Britain and America have finalized a key commercial pact that will ensure no levies on UK pharmaceutical shipments being sold in the US market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has agreed to raise funding on pharmaceuticals through the NHS. This commitment guarantees that tariffs on these key exports will stay at nothing for a period of 36 months.
This agreement comes after recent threats to significantly raise import taxes on branded pharmaceutical products, with potential rates mentioned up to double the cost.
"This deal with the United Kingdom strengthens the international landscape for cutting-edge drugs and establishes much-needed balance to U.S.–U.K. pharmaceutical trade," a release noted.
Commercial Significance
Medicines are one of the Britain's biggest goods shipped to the US, which is by far the biggest destination for large British pharmaceutical firms.
Statistics reveal that in the 12 months prior to last September, the UK exported pharmaceutical products totaling £11.1bn to the US. This amount represented nearly one-fifth of total UK exports in that period.
"This agreement secures work, boosts investment and paves the way for the UK to emerge as a worldwide center for medical research," a minister commented.
Detailed British Pledges
The agreement includes several key commitments from the UK:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it considers new therapies to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a goal to increase overall public funding on drugs from 0.3 percent of GDP to 0.6% over the coming ten years.
- Payback Limit: The percentage drug companies must pay back to the NHS to stay within budget will be limited at 15%. In the past, refunds topped 20%.
Industry Background
The pact takes place against a ongoing row between the pharmaceutical industry and the ministers over spending levels and approval rates.
This friction were intensified by assertions that American patients were charged several times more for the equivalent treatments than consumers in the UK and Europe.
Recently, several significant manufacturing plans in the UK have been delayed or cancelled, while substantial investments have been pledged toward projects in the United States.
A senior figure publicly accepted that the NHS had to invest a greater share on treatments, noting that its spending on drugs had declined as a share of its overall budget over the last ten years.
